210 related articles for article (PubMed ID: 12960733)
41. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin.
David-Cordonnier MH; Gajate C; Olmea O; Laine W; de la Iglesia-Vicente J; Perez C; Cuevas C; Otero G; Manzanares I; Bailly C; Mollinedo F
Chem Biol; 2005 Nov; 12(11):1201-10. PubMed ID: 16298299
[TBL] [Abstract][Full Text] [Related]
42. Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: new molecular insight into the mechanism of action.
Martínez-Serra J; Maffiotte E; Martín J; Bex T; Navarro-Palou M; Ros T; Plazas JM; Vögler O; Gutiérrez A; Amat JC; Ramos R; Saus C; Ginés J; Alemany R; Diaz M; Besalduch J
Eur J Pharmacol; 2011 May; 658(2-3):57-64. PubMed ID: 21371453
[TBL] [Abstract][Full Text] [Related]
43. Trabectedin: Supportive care strategies and safety profile.
Jordan K; Jahn F; Jordan B; Kegel T; Müller-Tidow C; Rüssel J
Crit Rev Oncol Hematol; 2015 Jun; 94(3):279-90. PubMed ID: 25794812
[TBL] [Abstract][Full Text] [Related]
44. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
Taamma A; Misset JL; Riofrio M; Guzman C; Brain E; Lopez Lazaro L; Rosing H; Jimeno JM; Cvitkovic E
J Clin Oncol; 2001 Mar; 19(5):1256-65. PubMed ID: 11230466
[TBL] [Abstract][Full Text] [Related]
45. Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells.
Atmaca H; Uzunoglu S
Eur Cytokine Netw; 2014 Mar; 25(1):1-7. PubMed ID: 24941346
[TBL] [Abstract][Full Text] [Related]
46. The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability.
Hurley LH; Zewail-Foote M
Adv Exp Med Biol; 2001; 500():289-99. PubMed ID: 11764956
[TBL] [Abstract][Full Text] [Related]
47. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
Le Cesne A; Blay JY; Judson I; Van Oosterom A; Verweij J; Radford J; Lorigan P; Rodenhuis S; Ray-Coquard I; Bonvalot S; Collin F; Jimeno J; Di Paola E; Van Glabbeke M; Nielsen OS
J Clin Oncol; 2005 Jan; 23(3):576-84. PubMed ID: 15659504
[TBL] [Abstract][Full Text] [Related]
48. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
Izbicka E; Lawrence R; Raymond E; Eckhardt G; Faircloth G; Jimeno J; Clark G; Von Hoff DD
Ann Oncol; 1998 Sep; 9(9):981-7. PubMed ID: 9818072
[TBL] [Abstract][Full Text] [Related]
49. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
[TBL] [Abstract][Full Text] [Related]
51. Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells.
Acikgoz E; Guven U; Duzagac F; Uslu R; Kara M; Soner BC; Oktem G
PLoS One; 2015; 10(10):e0141090. PubMed ID: 26485709
[TBL] [Abstract][Full Text] [Related]
52. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
Sessa C; De Braud F; Perotti A; Bauer J; Curigliano G; Noberasco C; Zanaboni F; Gianni L; Marsoni S; Jimeno J; D'Incalci M; Dall'ó E; Colombo N
J Clin Oncol; 2005 Mar; 23(9):1867-74. PubMed ID: 15774779
[TBL] [Abstract][Full Text] [Related]
53. The efficacy of trabectedin in treating ovarian cancer.
Teplinsky E; Herzog TJ
Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689
[TBL] [Abstract][Full Text] [Related]
54. Going further in the knowledge of Yondelis®; what's new in daily clinical practice?
Blay JY
Future Oncol; 2014 Jun; 10(8 Suppl):s13-7. PubMed ID: 25048044
[TBL] [Abstract][Full Text] [Related]
55. Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
Martin-Liberal J; Judson I
Expert Opin Drug Saf; 2013 Nov; 12(6):905-11. PubMed ID: 23937190
[TBL] [Abstract][Full Text] [Related]
56. Unique features of trabectedin mechanism of action.
Larsen AK; Galmarini CM; D'Incalci M
Cancer Chemother Pharmacol; 2016 Apr; 77(4):663-71. PubMed ID: 26666647
[TBL] [Abstract][Full Text] [Related]
57. Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.
Vincenzi B; Badalamenti G; Armento G; Silletta M; Spalato Ceruso M; Catania G; Napolitano A; Maltese G; Valeri S; Incorvaia L; Santini D; Tonini G
Oncology; 2018; 95(1):1-7. PubMed ID: 29510410
[TBL] [Abstract][Full Text] [Related]
58. Trabectedin: an anticancer drug from the sea.
Ganjoo KN; Patel SR
Expert Opin Pharmacother; 2009 Nov; 10(16):2735-43. PubMed ID: 19743937
[TBL] [Abstract][Full Text] [Related]
59. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
Baruchel S; Pappo A; Krailo M; Baker KS; Wu B; Villaluna D; Lee-Scott M; Adamson PC; Blaney SM
Eur J Cancer; 2012 Mar; 48(4):579-85. PubMed ID: 22088484
[TBL] [Abstract][Full Text] [Related]
60. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.
Le Cesne A; Domont J; Cioffi A; Bonvalot S; Terrier P; Ray-Coquard I; Alfaro V; Lebedinsky C; Santabarbara P; Blay JY
Drugs Today (Barc); 2009 Jun; 45(6):403-21. PubMed ID: 19649331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]